CTSE (Cathepsin E) is a gene located on chromosome 1q31.3 that encodes an aspartic protease belonging to the pepsin superfamily. Unlike other cathepsins that are widely expressed, Cathepsin E exhibits a more restricted tissue distribution, with high expression in immune cells (particularly macrophages and dendritic cells), gastric mucosa, and lower expression in various brain regions including the hippocampus and olfactory bulb. The gene is catalogued as NCBI Gene ID 1519 and OMIM 131100 [@hook2002].
| Cathepsin E | |
|---|---|
| Gene Symbol | CTSE |
| Full Name | Cathepsin E |
| Chromosome | 1q31.3 |
| NCBI Gene ID | [1519](https://www.ncbi.nlm.nih.gov/gene/1519) |
| OMIM | [131100](https://omim.org/entry/131100) |
| Ensembl ID | ENSG00000105638 |
| UniProt ID | [P10111](https://www.uniprot.org/uniprot/P10111) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Inflammatory Disorders |
Cathepsin E is a member of the aspartic protease family characterized by two conserved Asp-Thr-Gly motifs in the active site. The enzyme is synthesized as a preproenzyme (426 amino acids) and undergoes proteolytic processing to form the mature enzyme. Unlike cathepsin D, another lysosomal aspartic protease, cathepsin E is predominantly localized in endosomal compartments and the trans-Golgi network rather than in lysosomes. This subcellular distribution suggests distinct functional roles in antigen processing and intracellular protein degradation [@ctsestructure2021].
As an aspartic protease, cathepsin E utilizes two aspartate residues in the active site to catalyze peptide bond hydrolysis. The enzyme exhibits optimal activity at acidic pH (pH 3.5-5.0) but retains partial activity at neutral pH, which is relevant to its function in extracellular compartments and certain disease states. Substrate specificity studies have identified preferences for hydrophobic and aromatic residues at the P1 and P1' positions, with particular affinity for sequences found in amyloid precursor protein (APP) processing sites [@ctsestructure2021].
Cathepsin E expression is highly cell-type specific:
Expression data is available from the Allen Human Brain Atlas [@zhang2005] and shows region-specific patterns that may be relevant to neurodegenerative disease susceptibility.
Cathepsin E has been implicated in both the production and degradation of amyloid-beta (Aβ) peptides, the central pathogenic molecules in Alzheimer's disease. The enzyme can:
Direct Aβ degradation: Cathepsin E can cleave Aβ peptides, particularly Aβ1-40 and Aβ1-42, potentially reducing extracellular amyloid plaque burden. This antiamyloidogenic function contrasts with some findings for cathepsin B [@muellersteiner2006].
APP processing: Cathepsin E can process amyloid precursor protein (APP) through non-amyloidogenic pathways, potentially reducing Aβ generation. The enzyme interacts with APP in endosomal compartments where Aβ production primarily occurs.
Microglial regulation: A 2022 study demonstrated that microglial cathepsin E plays a critical role in regulating neuroinflammation and amyloid-beta production in AD. Knockdown of cathepsin E in microglia reduced Aβ generation while decreasing pro-inflammatory cytokine release, suggesting a complex dual role in disease pathogenesis [@microglialctse2022].
Cathepsin E is increasingly recognized as a key regulator of neuroinflammation in AD:
Cathepsin E shares overlapping substrate specificity with cathepsin D, another aspartic protease implicated in AD. Both enzymes can degrade Aβ and process APP, but they exhibit distinct expression patterns and subcellular localization. Studies in cathepsin D-deficient mice suggest compensatory upregulation of cathepsin E, indicating potential functional redundancy [@cathepsind2020].
In Parkinson's disease, cathepsin E expression is altered in dopaminergic neurons of the substantia nigra. The enzyme may contribute to:
Cathepsin E represents a potential therapeutic target for AD due to its roles in Aβ metabolism and neuroinflammation. However, the dual nature of its functions—protective Aβ degradation versus pro-inflammatory signaling—creates complexity for therapeutic modulation. Selective inhibitors must consider these opposing effects [@cathepsininhibitors2023].
Elevated cathepsin E levels in cerebrospinal fluid (CSF) and plasma have been detected in AD patients, suggesting potential utility as a biomarker for disease diagnosis and progression. The enzyme's association with microglial activation makes it particularly relevant for tracking neuroinflammation.
The selective vulnerability of specific brain regions in AD correlates with cathepsin E expression patterns. The hippocampus, which shows early pathology in AD, exhibits moderate cathepsin E expression that may influence regional susceptibility to amyloid toxicity.
| Disease | Mechanism | Evidence Level |
|---|---|---|
| Alzheimer's Disease | Aβ degradation, neuroinflammation, APP processing | Strong |
| Parkinson's Disease | Alpha-synuclein metabolism, lysosomal dysfunction | Moderate |
| Inflammatory Disorders | Immune cell function, cytokine regulation | Strong |
| Cancer | Antigen presentation, immune evasion | Strong |